scholarly journals IL-22 produced by type 3 innate lymphoid cells (ILC3s) reduces the mortality of type 2 diabetes mellitus (T2DM) mice infected with Mycobacterium tuberculosis

2019 ◽  
Vol 15 (12) ◽  
pp. e1008140 ◽  
Author(s):  
Deepak Tripathi ◽  
Rajesh Kumar Radhakrishnan ◽  
Ramya Sivangala Thandi ◽  
Padmaja Paidipally ◽  
Kamakshi Prudhula Devalraju ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Mycobacterium Tuberculosis ◽  
Innate Lymphoid Cells ◽  
Lymphoid Cells ◽  
Type 3

scholarly journals Type 2 Diabetes Mellitus

2019 ◽  
Author(s):  
Vishwanath Venketaraman ◽  
Aram Yegiazaryan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Mycobacterium Tuberculosis ◽  
Tuberculosis Infection ◽  
Mycobacterium Tuberculosis Infection ◽  
Altered Metabolism

Uncontrolled Type 2 diabetes is associated with altered metabolism resulting in microvascular and macrovascular diseases and enhanced susceptibility to Mycobacterium tuberculosis infection.

scholarly journals BCG vaccination reduces the mortality of Mycobacterium tuberculosis–infected type 2 diabetes mellitus mice

JCI Insight ◽  
2020 ◽  
Vol 5 (5) ◽  
Author(s):  
Rajesh Kumar Radhakrishnan ◽  
Ramya Sivangala Thandi ◽  
Deepak Tripathi ◽  
Padmaja Paidipally ◽  
Madeline Kay McAllister ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Mycobacterium Tuberculosis ◽  
Bcg Vaccination

scholarly journals Unwinding Complexities of Diabetic Alzheimer by Potent Novel Molecules

2020 ◽  
Vol 35 ◽  
pp. 153331752093754 ◽  
Author(s):  
Sumeet Gupta ◽  
Anroop Nair ◽  
Vikas Jhawat ◽  
Nazia Mustaq ◽  
Abhishek Sharma ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Neuroprotective Effect ◽  
Cross Sectional ◽  
New Drug ◽  
Drug Molecules ◽  
Neurochemical Changes ◽  
Type 3

Diabetes mellitus is one of the aggressive disorders in global society. No pharmacotherapy is available for permanent diabetes cure, although management is possible with drugs and physical activities. One of the recent complications noticed in type 2 diabetes mellitus includes diabetes-induced Alzheimer. It has been proposed that the possible diabetes-induced Alzheimer could be of type 3 diabetes. A variety of cross-sectional studies have proved that type 2 diabetes mellitus is one of the factors responsible for the pathophysiology of Alzheimer. New drug molecules developed by pharmaceutical companies with adequate neuroprotective effect have demonstrated their efficacy in treatment of Alzheimer in various preclinical diabetic studies. Patients of type 2 diabetes mellitus may show the benefit with existing drugs but may not cause complete cure. Extensive studies are being carried out to find new drug molecules that show their potential as antidiabetic drug and could treat type 2 diabetes–induced Alzheimer as well. This review provides an overview about the recent advancement in pharmacotherapy of diabetes-induced Alzheimer. The pathomechanistic links between diabetes and Alzheimer as well as neurochemical changes in diabetes-induced Alzheimer are also briefed.

scholarly journals INSIDENSI TB PARU KASUS BARU PADA PASIEN DENGAN DM TIPE 2 DI SALAH SATU RUMAH SAKIT SWASTA CIKAMPEK

2019 ◽  
Vol 4 (2) ◽  
Author(s):  
Himyatul Hidayah ◽  
Surya Amal
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Mycobacterium Tuberculosis ◽  
Pulmonary Tuberculosis ◽  
Private Hospital ◽  
Tuberculosis Patients ◽  
Pulmonary Tb ◽  
Hiv Aids

Penyakit tuberkulosis (TB) merupakan penyakit menular yang disebabkan oleh Mycobacterium tuberculosis, menjadi penyakit infeksi penyebab kematian kedua di dunia setelah HIV-AIDS. Prevalensi kejadian TB di Indonesia menempati urutan ketiga setelah India dan China. Diabetes mellitus diperkirakan penyebab 15% kasus tuberkulosis saat ini, karena penyakit diabetes mellitus dapat merusak pertahanan host. Tujuan penelitian ini untuk mengetahui insidensi TB paru kasus baru dengan DM tipe 2 di salah satu rumah sakit swasta Cikampek. Instrumen penelitian yang digunakan adalah data sekunder rekam medik pasien TB paru kasus baru yang menjalani rawat jalan selama bulan April – September 2017 di Poli Penyakit Dalam salah satu rumah sakit swasta Cikampek. Hasil penelitian ini menunjukkan bahwa dari 83 pasien TB paru kasus baru terdapat 26 pasien TB paru kasus baru dengan DM Tipe 2.  Frekuensi TB paru kasus baru dengan DM tipe 2 lebih banyak pada kelompok jenis kelamin perempuan (53,85%), usia >54 tahun (65,39%), hasil pemeriksaan BTA sputum negatif (61,50%), lamanya pengobatan yang dianjurkan >8 bulan (53,85%).  Disimpulkan bahwa insidensi tuberkulosis paru kasus baru dengan DM tipe 2 rawat jalan di Poli Penyakit Dalam salah satu rumah sakit swasta Cikampek selama bulan April – September 2017 adalah sebesar 31,33%. Kata Kunci: Insidensi, Tuberkulosis paru, Diabetes mellitus tipe 2 Tuberculosis (TB) is an infectious disease caused by mycobacterium tuberculosis, it became the second leading cause of death in the world after HIV-AIDS. The prevalence of incidence of TB in Indonesia ranked third after India and China. Diabetes mellitus thought to be the cause 15 % the case of tuberculosis at the present time, due to disease of diabetes mellitus can be damaging to defense host. The purpose of this study was to know the incidence of new cases of pulmonary TB with type 2 diabetes mellitus in one of the private hospital Cikampek. The research instrument used was secondary data from the medical records of new TB pulmonary outpatients during April - September 2017 in the polyclinic internal medicine in one of the private hospital Cikampek. The result of study indicate that of the 83 new cases of pulmonary tuberculosis patients there were 26 new cases of pulmonary tuberculosis patients with type 2 diabetes mellitus. The frequency of pulmonary tuberculosis a new case with type 2 DM be greater among a group of the female sex (53,85 %), the age of >54 years (65,39%), results smear sputum negative (61,50%), length of treatment recommended >8 months (53,85%). It was concluded that the incidence of new cases of pulmonary TB with type 2 diabetes mellitus outpatients care in one of the private hospital Cikampek during the month of April – September2017 was recorded at 31,33 %. Keywords: Incidence, Pulmonary tuberculosis, Type 2 diabetes mellitus

scholarly journals Type 3 Diabetes Mellitus: A Link Between Alzheimer's Disease and Type 2 Diabetes Mellitus

Cureus ◽  
2020 ◽  
Author(s):  
Omar Nisar ◽  
Hira Pervez ◽  
Bilvesh Mandalia ◽  
Muhammad Waqas ◽  
Harmandeep Kaur Sra
Keyword(s):  
Diabetes Mellitus ◽  
Alzheimer’S Disease ◽  
Type 2 Diabetes ◽  
Alzheimer's Disease ◽  
Type 2 Diabetes Mellitus ◽  
Type 3 Diabetes ◽  
Type 3

scholarly journals DR3 stimulation of adipose resident ILC2s ameliorates type 2 diabetes mellitus

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Pedram Shafiei-Jahani ◽  
Benjamin P. Hurrell ◽  
Lauriane Galle-Treger ◽  
Doumet Georges Helou ◽  
Emily Howard ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Adipose Tissue ◽  
Death Receptor ◽  
Lymphoid Cells ◽  
Low Grade ◽  
Group 2

Abstract Disturbances in glucose homeostasis and low-grade chronic inflammation culminate into metabolic syndrome that increase the risk for the development of type 2 diabetes mellitus (T2DM). The recently discovered group 2 innate lymphoid cells (ILC2s) are capable of secreting copious amounts of type 2 cytokines to modulate metabolic homeostasis in adipose tissue. In this study, we have established that expression of Death Receptor 3 (DR3), a member of the TNF superfamily, on visceral adipose tissue (VAT)-derived murine and peripheral blood human ILC2s is inducible by IL-33. We demonstrate that DR3 engages the canonical and/or non-canonical NF-κB pathways, and thus stimulates naïve and co-stimulates IL-33-activated ILC2s. Importantly, DR3 engagement on ILC2s significantly ameliorates glucose tolerance, protects against insulin-resistance onset and remarkably reverses already established insulin-resistance. Taken together, these results convey the potent role of DR3 as an ILC2 regulator and introduce DR3 agonistic treatment as a novel therapeutic avenue for treating T2DM.

Sign in / Sign up

Export Citation Format

Share Document